Financial Statements — IMRN
Balance Sheet
(in millions USD)| Metric | Q2
2024 |
|---|
| Cash & Equivalents | 15.21 |
| Inventory | 1.62 |
| Total Current Assets | 18.95 |
| Total Non-current Assets | 0.94 |
| Total Assets | 19.88 |
| Total Current Liabilities | 2.22 |
| Total Non-current Liabilities | 0.13 |
| Total Liabilities | 2.36 |
| Retained Earnings | (74.13) |
| Total Stockholder Equity | 17.53 |
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2
2024 |
|---|
| Total Revenue | 2.36 |
| Cost of Revenue* | 0.78 |
| Gross Profit | 1.58 |
| Research & Development | 2.65 |
| Total Operating Expenses* | 3.60 |
| Operating Income | (2.02) |
| Pretax Income | (2.07) |
| Net Income | (2.07) |
| Basic EPS | (0.91) |
| Diluted EPS | (0.91) |
* Derived from reported values
Cash Flow Statement
(in millions USD)| Metric | Q2
2024 |
|---|
| Operating Cash Flow | (2.00) |
| Investing Cash Flow | 0.15 |
| Financing Cash Flow | (0.02) |